Moreover, early clinical data in a small patient population suggests that targeted therapy with BRAF/MEK inhibitors may work in synergy with checkpoint inhibitors and this triplet therapy may improve survival in patients with metastatic melanoma [100]. This evidence concerns the gene MAP2K7 and metastatic melanoma.